Genscript Biotech Corporation

1548

KYG3825B1059

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 07:46:53 10/02/2026 GMT			5-day change	1st Jan Change
12.50 ^HKD	+2.04%		+0.48%	+0.72%

01-22	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT
15/10/25	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT

GenScript Associate Books $524 Million in Q3 CARVYKTI Sales

Published on 10/15/2025 at 04:42 am BST

MT Newswires

Latest news about Genscript Biotech Corporation

01-22	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT
15/10/25	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT
14/10/25	Genscript Biotech Receives 480 Million Yuan Payment Under Sub-License Contract	MT
18/08/25	Genscript Biotech Corporation, H1 2025 Earnings Call, Aug 18, 2025
17/08/25	Genscript Biotech Corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08/08/25	GenScript Biotech Corporation Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology	CI
22/07/25	Genscript Expects to Swing to H1 Profit	MT
22/07/25	Genscript Biotech expects profit before tax of $175.4m-$204.6m in HY	RE
22/07/25	Genscript Biotech Corporation Provides Group Earnings Guidance for the Six Months Ended June 30, 2025	CI
17/07/25	GenScript Associate Books $439 Million in Q2 CARVYKTI Sales; Shares Gain 4%	MT
09/07/25	US lawmakers renew concerns about GenScript's ties to China	RE
30/06/25	Genscript Biotech Corporation's Zhenjiang ProBio Biotech Co., Limited and ProBio Nanjing Receives Payments of Approximately USD 213.8 Million Under the R&A Agreement	CI
30/06/25	Genscript Biotech Units Receive Payment Under Sub-License Contract	MT
12/06/25	Genscript Biotech Grants Over 7.4 Million Restricted Shares Under Award Scheme	MT
04/06/25	Genscript Biotech Corporation Announces New 5-Year Survey Data for Carvykti in Cartitude-1 Study for Multiple Myeloma at 2025	CI
04/06/25	Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study	MT
29/05/25	Genscript Biotech Corporation Announces Board and Committee Changes, Effective 29 May 2025	CI
16/04/25	Genscript Biotech Associate Logs $369 Million in Q1 Sales of CARVYKTI	MT
09/04/25	Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide	MT
09/04/25	Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs	MT
19/03/25	GenScript Unveils Prime Editing Boost with the Broad Institute Deal	CI
12/03/25	Genscript Biotech Swings to Profit in 2024; Shares Down 4%	MT
11/03/25	Genscript Biotech Corporation, 2024 Earnings Call, Mar 12, 2025
11/03/25	Genscript Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
11/03/25	Genscript Biotech Corporation Announces Board and Board Committee Changes	CI

Chart Genscript Biotech Corporation

Duration

Period

1548: Dynamic Chart

Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

Employees

5,769

Sector

Biotechnology & Medical Research

Calendar

03-26 - Q4 2025 Earnings Release (Projected)

More about the company